Validation of the has-bled scale for the assessment of bleeding risk in patients on anticoagulation therapy with a diagnosis of venous thromboembolic disease
Revista de Investigación Clínica · 2024
DOI: 10.24875/ric.24000147 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Revista de Investigación Clínica, 2024. Verfasst von Stephanie Ortiz-Gómez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia, Bogotá, Colombia. Hauptthemen laut MEDLINE: Venous Thromboembolism, Hemorrhage, Anticoagulants. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Several models have been developed to assess bleeding risk in patients with venous thromboembolism, such as HAS-BLED, but their external validity has not been adequately assessed.
Objective
The objective of the study was to evaluate the discriminative ability and calibration of the HAS-BLED scale for predicting 1-month bleeding risk in patient's anticoagulated for venous thromboembolism. Materials and Methods: External validation study of a prediction model based on a retrospective cohort of patients with venous thromboembolism treated between November 2019 and January 2022. Calibration of the HAS-BLED scale was evaluated using the Hosmer-Lemeshow test and the ratio of observed to expect events within each risk category. Discriminatory ability was assessed using the area under the curve (AUC) of a receiver operating characteristic curve.
Results
We included 735 patients (median age 64 years, female sex 55.2%), pulmonary embolism was diagnosed in most patients (60.7%), and 4.9% presented bleeding events. Regarding calibration, the HAS-BLED scale systematically underestimates the risk both in the general population (ROE 3.76, p < 0.001) and in cancer patients (ROE 4.16). The Hosmer-Lemeshow test rejected the hypothesis of adequate calibration (p < 0.001). Discriminatory ability was limited both in the general population (AUC = 0.57, 95% confidence interval [CI]: 0.48-0.66) and in the subgroup with active cancer (AUC = 0.53, 95% CI: 0.36-0.69).
Conclusion
The HAS-BLED scale in patients with venous thromboembolism underestimates the risk of bleeding at 1 month and has a low ability to discriminate high-risk patients. Cautious interpretation of the scale is recommended until additional evidence is available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia, Bogotá, Colombia.
- Department of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.
Zitieren
APA
Ortiz-Gómez, S., Ruiz-Talero, P., & Muñoz, O. (2024). Validation of the has-bled scale for the assessment of bleeding risk in patients on anticoagulation therapy with a diagnosis of venous thromboembolic disease. Revista de Investigación Clínica. https://doi.org/10.24875/ric.24000147
Vancouver
Ortiz-Gómez S, Ruiz-Talero P, Muñoz O. Validation of the has-bled scale for the assessment of bleeding risk in patients on anticoagulation therapy with a diagnosis of venous thromboembolic disease. Revista de Investigación Clínica. 2024. doi:10.24875/ric.24000147
BibTeX
@article{OrtizGmez2024,
author = {Ortiz-Gómez, Stephanie and Ruiz-Talero, Paula and Muñoz, Oscar},
title = {Validation of the has-bled scale for the assessment of bleeding risk in patients on anticoagulation therapy with a diagnosis of venous thromboembolic disease},
journal = {Revista de Investigación Clínica},
year = {2024},
doi = {10.24875/ric.24000147}
}
EUVIMED